In addition, the simultaneous delivery of celecoxib and anti-PD-1 mAbs significantly enhanced anti-tumor efficacy, as manifested by significantly reduced tumor size, as well as complete regression of some mouse tumors [152]. Here, PDCD1 is linked to neoplasm.